Author Affiliation: Department of Internal Medicine-Nephrology, Patras University Hospital, Patras, Greece (firstname.lastname@example.org).
To the Editor: The Paricalcitol Capsule Benefits in Renal Failure-Induced Cardiac Morbidity (PRIMO) trial by Dr Thadhani and colleagues1 failed to show any improvement in left ventricular mass index (LVMI) in patients with chronic kidney disease (CKD) after daily oral administration of paricalcitol for 48 weeks. Similar outcomes have been reported in other prospective studies of patients with CKD receiving erythropoiesis-stimulating agents.2,3
Fourtounas C. Vitamin D Therapy and Cardiac Function in Chronic Kidney Disease. JAMA. 2012;307(21):2253. doi:10.1001/jama.2012.4168